Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer [0.03%]
立体定向体部放射治疗用于早期非小细胞肺癌的效果：调强放疗与三维适形放疗比较
Michael Mix,Sean Tanny,Tamara Nsouli et al.
Michael Mix et al.
Introduction: The treatment techniques used for stereotactic body radiation therapy (SBRT) for early-stage lung cancer continue to evolve. In this study, clinical outcomes following SBRT were evaluated according to the us...
Chiara Baldovini,Giulio Rossi,Alessia Ciarrocchi
Chiara Baldovini
Pulmonary sarcomatoid carcinoma (PSC) is a heterogeneous category of primary lung cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most recent 2015 World Health Organization (WHO) classification, PSC incl...
Natthaya Triphuridet,Claudia Henschke
Natthaya Triphuridet
Lung cancer remains the leading cause of cancer incidence and mortality worldwide. Approximately 60% of the world's new cases of lung cancer and deaths from it are expected in Asia in 2018. Currently, lung cancer screening using low-dose co...
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations [0.03%]
携带二次CTNNB1 p.S45V和三次ALK p.I1171N突变的TKI耐药性重排肺腺癌
Madhu M Ouseph,Angela Taber,Humera Khurshid et al.
Madhu M Ouseph et al.
Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) is an important molecular subgroup of tumors that are typically sensitive to tyrosine kinase inhibitors (TKIs). Although a substantial portion of patients benefi...
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors [0.03%]
评估肿瘤体积(PTV)作为非小细胞肺癌(NSCLC)患者预测PD-1抑制剂疗效的预处理标志物的回顾性研究
Misako Nagasaka,Nadine Abdallah,Marcus Crosby et al.
Misako Nagasaka et al.
Introduction of hypothesis: Little information is available regarding the imaging characteristics that assist in differentiating responders from non-responders. We hypothesized that patients with higher pretreatment tumor...
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date [0.03%]
恩曲替尼及其在ROS1阳性NSCLC治疗中的潜力：迄今为止的证据
Francesco Facchinetti,Luc Friboulet
Francesco Facchinetti
ROS1 inhibition provides impressive survival benefits in ROS1-rearranged non-small cell lung cancer (NSCLC) patients. Crizotinib is the only tyrosine kinase inhibitor (TKI) approved by both FDA and EMA for the treatment of ROS1-positive lun...
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients [0.03%]
吸烟对印尼未经治疗的肺癌患者中K-RAS和EGFR突变频率和谱系的影响
Najmiatul Masykura,Jamal Zaini,Elisna Syahruddin et al.
Najmiatul Masykura et al.
Background: Indonesia has the highest cigarette consumption in the world. We explored the clinical impact of smoking on the prevalence of EGFR and K-RAS mutations and survival in this prospective study. Methods: 143 treatment naive lung can...
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers [0.03%]
polo样激酶1在非小细胞肺癌中的抑制：作用机制和预测生物标志物的出现
Jan A Stratmann,Martin Sebastian
Jan A Stratmann
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Due to often unspecific disease symptoms, locally advanced or metastatic disease is diagnosed in the majority of all cases. Palliative treatment options comp...
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer [0.03%]
派姆单抗联合化疗成为晚期非小细胞肺癌患者的新标准治疗方案
Frank Weinberg,Shirish Gadgeel
Frank Weinberg
Until recently, the treatment of patients with advanced non-small-cell lung cancer (NSCLC) whose tumors did not have a targetable genetic alteration was cytotoxic chemotherapy alone. This treatment provided only modest survival benefit. The...
Pain management in patients with malignant mesothelioma: challenges and solutions [0.03%]
恶性间皮瘤患者的疼痛管理：挑战与对策
J Saunders,M Ashton,C Hall et al.
J Saunders et al.
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a considerable symptom burden and poor prognosis. Focus on maintaining patients' quality of life and pain control is therefore paramount. Pain management in MPM is complex du...